Multicenter MRI for Characterization Of Residual NeuroblasToma after Surgery

• Conditions: C74; Malignant neoplasm of adrenal gland

• Registration Number: DRKS00034345
• Lead Sponsor: niversitätsklinikum Tübingen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-05-29
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Clinical indication for MRI in preoperative MRI imaging before local therapy for high-risk/+IDRF neuroblastoma
or postoperative MRI imaging after local therapy of a high-risk/+IDRF neuroblastoma to evaluate a possible tumor residual
- Presence of all necessary laboratory parameters (creatinine/GFR without evidence of high-grade renal insufficiency; GFR >30 ml/min)
- Written consent to the study from the patient and/or legal guardian

Exclusion Criteria

-Presence of implants that are not MR-compatible or any type of metal in or on the body (e.g. pacemakers, artificial heart valves, metal prostheses, implanted magnetic metal parts, etc. that are not MR-compatible)
- Non-compliance of the patient for an MRI examination and any study-related extension of the examination time.
- No written consent to the study from the patient and/or legal guardian

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
- Multiparametric analysis of neuroblastic tumors for tissue differentiation<br>- Establishment of a standardized preoperative and early postoperative MRI for the analysis and evaluation of tumor residuals with influence on further therapy

Secondary Outcome Measures

Name	Time	Method
- Establishment of novel diffusion-based parameters<br>- T1 and T2 mapping of neuroblastic tumors for vitality assessment, response, prognosis and tumor differentiation